References
- http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071597.pdf
- http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf
- Greaves P, Williams A, Eve M. First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov. 2004 Mar;3(3):226–236.
- Parasuraman S. Toxicological screening. J Pharmacol Pharmacother. 2011 Apr;2(2):74–79.
- Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nature Rev Drug Discovery. 2014;13:419–431.
- Waring MJ, Arrowsmith J, Leach AR, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature Rev Drug Discov. 2015;14:475–486.
- Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000;32(1):56–67.
- Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nature Rev Drug Discov. 2005;4:489–499.
- Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev. 2013;65(2):779–808.
- Alderton W, Holder J, Lock R, et al. Reducing attrition through early assessment of drug safety. Highlights from the society of medicines research symposium, held on march 13th, 2014 – national heart & lung institute, Kensington, London, UK. Drugs of the Future. 2014;39(5):373–377.
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711–715.
- Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. Jama. 2002;287(17):2215–2220.
- Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. Jama. 2002 1; 287(17):2273–2275.
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998;279(15):1200–1205.
- Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Bmj. 2004;329(7456):15–19.
- Miguel A, Azevedo LF, Araújo M, et al. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1139–1154.
- US DailyMed. 2016. Available from https://dailymed.nlm.nih.gov/dailymed/index.cfm.
- http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173074.htm.
- http://www.fda.gov/ohrms/dockets/dailys/04/sep04/091704/81n-0022-m000007-vol95.pdf.
- http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/12/news_detail_000923.jsp&mid=WC0b01ac058004d5c1.
- Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2(5):205–207.
- http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500018335.pdf.
- McNaughton R, Huet G, Shakir S. BMJ Open 2014;4:e004221. 10.1136/bmjopen-2013-004221http://www.thepharmaletter.com/article/b-ms-to-withdraw-nefazodone-in-europe.
- http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm106274.htm.
- http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126461.htm.
- http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500018391.pdf.
- http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/02/WC500074073.pdf.
- http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/11/news_detail_000087.jsp&mid=WC0b01ac058004d5c1.
- http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108877.htm.
- http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108879.htm.
- http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500012189.pdf.
- http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm.
- http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234350.htm.
- http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Tetrazepam_containing_medicinal_products/human_referral_prac_000015.jsp&mid=WC0b01ac05805c516f.
- Hamdam J, Sethu S, Smith T, et al. Safety pharmacology-current and emerging concepts. Toxicol Appl Pharmacol. 2013 Dec 1;273(2):229–241.
- Dykens JA, Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov Today. 2007;12:777–785.
- Amacher DE, Chalasani N. Drug-induced hepatic steatosis. Semin Liver Dis. 2014;34(2):205–214.
- Giampietri C, Starace D, Petrungaro S, et al. Necroptosis: molecular signalling and translational implications. Internat J Cell Biol. 2014;6 pages. Article ID 490275. 10.1155/2014/490275
- Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256:42–49.
- Kenna JG. Current concepts in drug-induced bile salt export pump (BSEP) interference. Current Protocols in Toxicology. 2014;61:23.7:23.7.1–23.7.15.
- Laskin DL. Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. Chem Res Toxicol. 2009 Aug;22(8):1376–1385.
- Pichler WJ Editor. (Bern) Drug hypersensitivity. Karger, Basel 2007. ISBN: 978-3-8055-8269-8. e-ISBN: 978-3-318-01454-9. 10.1159/isbn.978-3-318-01454-9
- Attia SM. Deleterious effects of reactive metabolites. Oxid Med Cell Longev. 2010;3(4):238–253.
- Hayes JD, McLellan LI. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res. 1999 Oct;31(4):273–300.
- Fulda S, Gorman AM, Hori O, et al. Cellular stress responses: cell survival and cell death. Int J Cell Biol. 2010:23 pages. Article ID 214074. DOI:10.1155/2010/214074
- Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol. 2010;(196):369–405. 10.1007/978-3-642-00663-0_12
- Xie Y, McGill MR, Dorko K, et al. Mechanisms of acetaminophen-induced cell death in primary human hepatocytes. Toxicol Appl Pharmacol. 2014 Sep 15;279(3):266–274.
- Jaeschke H, Williams CD, Ramachandran A, et al. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int. 2012 Jan;32(1):8–20.
- Uetrecht J. Role of animal models in the study of drug-induced hypersensitivity reactions. Aaps J. 2006 Jan 13;7(4):E914–21.
- Shenton JM, Teranishi M, Abu-Asab MS, et al. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem Res Toxicol. 2003 Sep;16(9):1078–1089.
- Roth RA, Ganey PE. Animal models of idiosyncratic drug-induced liver injury–current status. Crit Rev Toxicol. 2011 Oct;41(9):723–739.
- Metushi IG, Hayes MA, Uetrecht J. Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology. 2015 Apr;61(4):1332–1342.
- Chakraborty M, Fullerton AM, Semple K, et al. Drug-induced allergic hepatitis develops in mice when myeloid-derived suppressor cells are depleted prior to halothane treatment. Hepatology. 2015 Aug;62(2):546–557.
- Park BK, Boobis A, Clarke S, et al. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov. 2011 Apr;10(4):292–306.
- Sakatis MZ, Reese MJ, Harrell AW, et al. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chem Res Toxicol. 2012 Oct 15;25(10):2067–2082.
- O’Brien PJ, Irwin W, Diaz D, et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol. 2006 Sep;80(9):580–604.
- Gustafsson F, Foster AJ, Sarda S, et al. A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. Toxicol Sci. 2014 Jan;137(1):189–211.
- Dawson S, Stahl S, Paul N, et al. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos. 2012 Jan;40(1):130–138.
- Morgan RE, Van Staden CJ, Chen Y, et al. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216–241.
- Pohl LR, Satoh H, Christ DD, et al. The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol. 1988;28:367–387.
- Beeler A, Engler O, Gerber BO, et al. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol. 2006 Feb;117(2):455–462.
- Pavlos R, Mallal S, Ostrov D, et al. T cell-mediated hypersensitivity reactions to drugs. Annu Rev Med. 2015;66:439–454.
- Ulrich RG. Idiosyncratic toxicity: a convergence of risk factors. Annu Rev Med. 2007;58:17–34.
- Thompson RA, Isin EM, Li Y, et al. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact. 2011 Jun 30;192(1–2):65–71.
- Garside H, Marcoe KF, Chesnut-Speelman J, et al. Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes. Toxicol In Vitro. 2014 Mar;28(2):171–181.
- Hynes J, Nadanaciva S, Swiss R, et al. A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays. Toxicol In Vitro. 2013 Mar;27(2):560–569.
- Dambach DM, Andrews BA, Moulin F. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol Pathol. 2005;33(1):17–26.
- Zhu XW, Sedykh A, Liu SS. Hybrid in silico models for drug-induced liver injury using chemical descriptors and in vitro cell-imaging information. J Appl Toxicol. 2014 Mar;34(3):281–288.
- Chen M, Tung CW, Shi Q, et al. A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the ‘rule-of-two’ model. Arch Toxicol. 2014 Jul;88(7):1439–1449.
- Thompson RA, Isin EM, Li Y, et al. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol. 2012 Aug 20;25(8):1616–1632.
- Ansede JH, Smith WR, Perry CH, et al. An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes. Drug Metab Dispos. 2010 Feb;38(2):276–280.
- Barber JA, Stahl SH, Summers C, et al. Quantification of drug-induced inhibition of canalicular cholyl-l-lysyl-fluorescein excretion from hepatocytes by high content cell imaging. Toxicol Sci. 2015 Nov;148(1):48–59.
- Khetani SR, Kanchagar C, Ukairo O, et al. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci. 2013 Mar;132(1):107–117.
- Vernetti LA, Senutovitch N, Boltz R, et al. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med (Maywood). 2016 Jan;241(1):101–114.
- Traebert M, Dumotier B, Meister L, et al. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol. 2004 Jan 19;484(1):41–48.
- Mioulane M, Foldes G, Ali NN, et al. Development of high content imaging methods for cell death detection in human pluripotent stem cell-derived cardiomyocytes. J Cardiovasc Transl Res. 2012;5:593–604.
- Navarrete EG, Liang P, Lan F, et al. Screening drug-induced arrhythmia using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation. 2013 Sep 10;12811Suppl 1: S3–13. Erratum in: Circulation. 2014 Apr 15;129(15):e452.
- Cosgrove BD, King BM, Hasan MA, et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol. 2009 Jun 15;237(3):317–330.
- Soldatow VY, Lecluyse EL, Griffith LG, et al. In vitro models for liver toxicity testing. Toxicol Res (Camb). 2013 Jan 1;2(1):23–39.
- https://livertox.nih.gov/Troglitazone.htm.
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce.
- http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000679/WC500037902.pdf
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=725d4e73-6c83-477a-adc6-0ae4a133a844.
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25c0c6d5-f7b0-48e4-e054-00144ff8d46c.
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676ace4e-7706-742d-cab0-430dd1f83408.
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cad137fb-d18a-4286-94cf-7e79cdeea3f6.
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82fb6c54-3571-4ea1-9a1b-c21418133e84.
- McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995 Oct 26;333(17):1099–1105.
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866.
- Kenna JG, Stahl SH, Eakins JA, et al. Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists. J Pharmacol Exp Ther. 2015 Feb;352(2):281–290.
- Ulloa JL, Stahl S, Yates J, et al. Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition. NMR Biomed. 2013 Oct;26(10):1258–1270.
- Chen M, Zhang J, Wang Y, et al. The liver toxicity knowledge base: a systems approach to a complex end point. Clin Pharmacol Ther. 2013 May;93(5):409–412.
- Shoda LK, Woodhead JL, Siler SQ, et al. Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury. Biopharm Drug Dispos. 2014 Jan;35(1):33–49.
- Geenen S, Yates JW, Kenna JG, et al. Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and the potential glutathione-depletion biomarkers ophthalmic acid and 5-oxoproline in humans and rats. Integr Biol (Camb). 2013 Jun;5(6):877–888.